What Is Bioavailability? Definition and What Research Reports

The plain-language definition

Bioavailability is the share of a substance that actually makes it into the bloodstream in a usable, unchanged form after it has been administered. Swallowing a compound is not the same as absorbing it: some of it may never dissolve, some may not cross the gut wall, and some may be broken down by enzymes in the intestine or liver before it ever circulates. Bioavailability is the accounting term for what survives that journey. A substance injected directly into a vein bypasses those barriers entirely, so intravenous administration is used as the reference standard and is assigned a bioavailability of 100% by convention. Everything else is measured against it.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or a specific compound.

The formal pharmacological definition

In pharmacokinetics, bioavailability is usually written as F, the fraction of an administered dose that reaches systemic circulation as the intact parent compound. It has two standard forms:

• Absolute bioavailability — a non-intravenous route compared against the intravenous route of the same substance. It answers the question: what proportion arrived intact?
• Relative bioavailability — one formulation, salt or product compared against another formulation given by the same route. It answers: which preparation delivered more?

Both are derived from the plasma concentration–time curve. Researchers sample blood at intervals, plot concentration against time, and calculate the area under that curve (AUC), which represents total systemic exposure. Two other descriptors normally accompany it: C_max, the highest concentration observed, and T_max, the time at which that peak occurred. AUC captures how much; C_max and T_max capture how fast and how high.

Regulatory agencies use these same measurements when comparing a generic product to a reference product — a comparison usually described as bioequivalence rather than bioavailability, because the question is whether two products behave similarly rather than what the absolute fraction is.

What determines bioavailability

What the published literature reports

Formulation science

Much of the bioavailability literature is formulation work: attempts to raise the absorbed fraction of a compound that is otherwise poorly available orally. A 2020 study in the International Journal of Pharmaceutics examined supersaturated silica–lipid hybrids as a way to enhance oral bioavailability of abiraterone acetate, and researchers reported enhancement relative to comparator formulations. A 2022 report in Archives of Pharmacal Research described a nanostructured lipid carrier system used to enhance oral bioavailability of S(+)-zaltoprofen. A 2024 review in Skin Therapy Letter summarised advances in oral isotretinoin formulations aimed at enhancing bioavailability, a compound historically associated with variable absorption.

Delivery-vehicle research follows the same logic. A 2023 rat study in Medical Cannabis and Cannabinoids assessed absorption and bioavailability of a novel UltraShear nanoemulsion of cannabidiol, and the study measured systemic exposure in the animal model rather than in humans. Reviews of bioavailability of nanomaterials and of nanomedicine bioavailability, biotransformation and biokinetics have both argued that for nanoscale carriers the classical single-number definition is incomplete, because the carrier itself is transformed in biological media and its bioactivity does not track absorbed mass in a simple way.

Natural products and nutrition

Nutritional science uses the term heavily, often with an added complication: the substance may exist in multiple chemical forms with different absorption. A 2004 review in Proceedings of the Nutrition Society on folate bioavailability illustrated the point, since naturally occurring food folates and synthetic folic acid are not absorbed identically. A 2018 review in Molecules on bioavailability of tea catechins and its improvement summarised why these polyphenols show low systemic exposure and what strategies have been investigated. A 2022 review in Pharmaceutical Chemistry Journal covered bioavailability and safety of dihydroquercetin, pairing exposure data with safety discussion — a reminder that bioavailability and tolerability are separate questions.

Environmental and ecotoxicological usage

Outside pharmacology, "bioavailable" usually means "accessible to an organism or a process", not "absorbed into human plasma". A 2021 paper in Ground Water examined the bioavailability of dissolved, particulate and adsorbed organic carbon in groundwater systems, where the relevant consumer is microbial. A 2019 Chemosphere study combined chemical and toxicological methods to assess bioavailability of tolclofos-methyl using earthworms, and a 2017 Marine Pollution Bulletin study inferred bioavailability of microplastic-sorbed contaminants from biomarker gene expression in larval zebrafish. In all three, researchers measured an organism-level or process-level endpoint, not an AUC.

How the term is used in peptide discussions — and where it is misused

Peptides are, chemically, chains of amino acids, and the general pharmacological expectation is that peptide molecules face the same barriers listed above: proteolytic degradation, limited membrane permeability and first-pass metabolism. That is why bioavailability is discussed so often in peptide literature and why route of administration is a routine variable in peptide pharmacokinetic studies. Several recurring misuses of the word appear in non-scientific writing:

• Treating solubility as bioavailability. Whether a powder dissolves in a solvent describes a physical property in a vial. It says nothing about how much of the molecule reaches circulation intact.
• Treating absorption as bioavailability. A molecule can be absorbed across the gut wall and then largely destroyed by first-pass hepatic metabolism. Absorbed fraction and bioavailable fraction are different numbers.
• Quoting a percentage with no route, species or reference. A bioavailability figure is meaningless without stating the route it applies to, the species measured and whether it is absolute or relative.
• Assuming higher exposure equals greater effect. Reviews of nanoscale delivery have explicitly cautioned that the link between measured bioavailability and biological activity is not straightforward (PMID 36196113, PMID 31203796).
• Transferring animal figures to humans. Rodent pharmacokinetics, such as those measured in the cannabidiol nanoemulsion study (PMID 37942295), describe that animal model under those conditions.

Related terms

What a bioavailability figure does not tell readers

Bioavailability quantifies systemic exposure. It does not describe safety, efficacy, tissue distribution or appropriateness for any person. The dihydroquercetin review treated bioavailability and safety as two distinct sections of the same evidence base (PMID 35194263), and formulation papers that reported enhanced exposure did so as a pharmaceutical outcome, not as a clinical recommendation. Readers comparing figures across papers should note the route, species, dose framework and reference standard used, because those choices determine what the number means.

References

• Bioavailability and Safety of Dihydroquercetin (Review) (Pharmaceutical Chemistry Journal, 2022)
• The Bioavailability of Dissolved, Particulate, and Adsorbed Organic Carbon in Groundwater Systems (Ground Water, 2021)
• Bioavailability of nanomaterials: bridging the gap between nanostructures and their bioactivity (National Science Review, 2022)
• Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids (International Journal of Pharmaceutics, 2020)
• Enhancing Bioavailability: Advances in Oral Isotretinoin Formulations (Skin Therapy Letter, 2024)
• Absorption and Bioavailability of Novel UltraShear Nanoemulsion of Cannabidiol in Rats (Medical Cannabis and Cannabinoids, 2023)
• Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system (Archives of Pharmacal Research, 2022)
• Nanomedicine: Bioavailability, Biotransformation and Biokinetics (Current Drug Metabolism, 2019)
• Combination of chemical and toxicological methods to assess bioavailability of Tolclofos-methyl by earthworms (Chemosphere, 2019)
• Folate bioavailability (Proceedings of the Nutrition Society, 2004)
• Bioavailability of Tea Catechins and Its Improvement (Molecules, 2018)
• Assessment of microplastic-sorbed contaminant bioavailability through analysis of biomarker gene expression in larval zebrafish (Marine Pollution Bulletin, 2017)